Reading ACAD? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ACAD free→
Acadia Pharmaceuticals (ACAD)
NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Intact
$21.27+0.83%
Close 2026-06-15 · 1-day change
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
The bottom line
Recent financial performance is strong. Earnings quality is fragile, meaning profits lack cash support. Management's recent track record has been steady. Risk is moderate, and the sector backdrop is a headwind. Compared with sector peers, ACAD is below typical. Peer multiples imply a price about 112% below where it trades (it looks expensive on this basis); the read is rich. This analysis is provisional.
as of 2026-06-15
Quick facts
- Exchange
- NASDAQ
- Sector
- Health Care
- Industry
- Biotechnology
- Market cap
- $3.61B
- Employees
- —
- IPO date
- 2000-12-21
- Next earnings
- 2026-08-05
Price
Daily closes. Earnings/event dots are placed inline.
Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event
What's priced in
(what the market already expects)What it's worth (estimated)
A consensus fair price across 5 valuation methods, at three horizons. Current price $21.27. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
12-month· primaryexpensive
$10.01consensus
Range $9.50 – $15.10
vs price: +112% above
Method agreement — · 5 methods
No-growth: today's peer multiple on trailing earnings. The headline read.
3-yearfull
$19.73consensus
Range $13.38 – $26.53
vs price: +8% above
Method agreement — · 4 methods
Embeds projected growth. Leans optimistic by design. Upside context.
5-yearfair
How much to trust our fair value
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
Durable premiumlow confidence
At $21 the market pays 29× p/e — above the 13× p/e peer median but in line with its own 27× history. That premium reflects a durable franchise our peer-anchored $10 fair value understates; treat the 'expensive vs peers' read with low confidence. Analysts: $29–$35. Not investment advice.
Multiple (P/E)
28.8x
peer 12.9x · own history 27.1x
Premium
2.2x peer
1.1x its own history
Growth the price needs
112%
our forecast 22%
Our fair value
$10.01
range $9.50 – $16.00
Analyst range(a guide on our number, not a target)Our number is below the analyst range
How this stock is priced
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Long-term · 1–3 yr
expensiverich12-month view
What's priced inUnjustified
The market is pricing in roughly 112% near-term growth, well above our forecast of about 22%. This describes what's priced in, not a forecast of the move.
High fragilityrisk posture, not a price call
Flags: expensive valuation, weak execution quality, a turbulent sector regime (Heating).
Historical context
For similar setups historically (n=889): about 49% saw a 20%+ drawdown, and roughly 85% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
How strong is the business
(quality & execution)Factor signals
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Recent financial performance
strongOperating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
80th pctl · Health Care
Earnings quality
fragileOver the trailing year it converted 0.33x of net income into operating cash flow. Historically, Health Care names rated fragile grew net income 40% of the time over the next year (vs 56% for the rest of the cohort, n=1703).
21st pctl · Health Care
Macro sensitivity
Most sensitive to the broad stock market.
- the broad stock market: This stock moves with the broad market (high beta).
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
Management & capital allocation
neutralEarnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Earnings setup · pre-print positioning
forward-looking
Strongly bearishEPS revised -66.2% / 30d, n=11for period ending 2026-06-30
Why this setup
Consensus revisions
EPS estimate $0.11 → $0.04 (-66.2% / 30d). 1 raised, 5 cut, 11 covering analysts.
Rating actions
0 upgrades, 0 downgrades / 30d. 76% of analysts rate Buy.
Material events
0 positive, 0 negative / 30d.
Divergence: fundamentals are strong but estimates are being cut. Worth reading the recent material events.
Sector context
Intermediate · WeeklySector phase: health care is in (~0.5 years in phase).
Management scorecard
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Long-term · 1–3 yr
Overall: neutral
- Capital allocation
- neutral
- Earnings discipline
- neutral
- Margin discipline
- strong
- Balance sheet
- weak
- Post-call reaction
- strong
A guidance track record builds as the company issues and delivers on guidance.
How bumpy is the path
(risk while you hold it)Risk: how this stock moves
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Intermediate · WeeklyLong-term · 1–3 yr
On a typical day, $10k can swing ±$153.
How much price usually moves either way.
On a bad day, this stock has moved -$331.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $2,758.
Deepest peak-to-trough drop in the last year.
moderateas of 2026-06-15
Past results, not a forecast. Not investment advice.
What would change the read
(catalysts & re-read triggers)What changed
The most important moves since the prior daily snapshot.
Short-term · Daily
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
What to watch next
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Intermediate · Weekly
- UpsideHigh confidenceMonthsactive 4d
Watch for Phase 2 topline results from remlifanserin study
Why it matters: These results will show if remlifanserin is effective for Alzheimer’s disease psychosis. This could impact future sales and pipeline value.
What confirms / what disproves
Confirms:The Phase 2 study shows that remlifanserin works well.
Disproves:The Phase 2 study shows that remlifanserin does not work well.
Earnings call
News catalysts
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for ACAD yet.
This sector is also watching
- Watch for revenue growth re-acceleration in Health Care
What could change this view
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Intermediate · Weekly
Upside triggers
- If sector bellwethers like VRTX, REGN, and ARGX keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting ACAD and other Healthcare names. Worth watching these names for early signals.
- If ACAD raises forward guidance on the next earnings call (currently NEW as of 2026-05-06), that's a momentum boost. Street estimates typically follow guidance up and the stock tends to re-rate higher.
Downside triggers
- If ACAD cuts guidance on the next call (currently NEW as of 2026-05-06), that's a meaningful negative. The Street tends to walk down estimates and the stock usually takes a leg lower.
- If sector bellwethers like VRTX, REGN, and ARGX start missing or guiding lower, the Healthcare tailwind helping ACAD and other Healthcare names could fade. Watch these names for early warning.
- If ACAD misses again next quarter like this past one (a big miss of -60% on the 2026-03-31 print), expect continued pressure. The Street usually keeps walking estimates down after consecutive misses.
Recent events
(material 8-K / filing activity)Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-05-2919d agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) On May 29, 2026, Acadia Pharmaceuticals Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As further described in
Executive changeneutral
Score history
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
+3.1 vs last weeklatest as of 2026-06-15
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.